Neurophet AQUA

Neurophet AQUA is an advanced medical software that automates the volumetric analysis of brain structures from T1-weighted MR images using a deep learning-based segmentation pipeline. Its purpose is to provide clinicians and researchers with quantitative morphometric data and comparisons to normative references, thereby supporting the assessment of brain MRIs in clinical and research settings.

Neurophet AQUA is a medical image processing software designed for the automated analysis of brain Magnetic Resonance (MR) images. Its core function is to perform automatic labeling, visualization, and volumetric quantification of segmentable brain structures derived from T1-weighted MRI series. The software employs a proprietary internal pipeline powered by deep learning algorithms for precise segmentation, followed by volume calculation and the generation of detailed morphometric reports. These reports can include comparisons of an individual's brain structure volumes against age and gender-matched reference percentile data, offering a quantitative basis for neurological assessment. The outputs, including color-coded segmented images and comprehensive morphometric reports, are compatible with Picture Archive and Communications Systems (PACS), facilitating integration into clinical workflows. Neurophet AQUA is intended as a supportive tool for clinicians in both routine patient care and clinical trial research for assessing structural MRIs. Performance evaluations have validated its methodology, showing segmentation accuracy (Dice coefficient) of 75-85% for major cortical regions and 80-90% for major subcortical structures compared to expert manual segmentations. Furthermore, its reproducibility on repeated scans for major subcortical structures demonstrated mean percentage absolute volume differences between 1-5%, underscoring its reliability in quantifying brain morphometry.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the deep learning model in Neurophet AQUA specifically address variability in MR image quality and artifacts, beyond general data augmentation techniques mentioned for the training dataset?; What is the specific composition, size, and demographic diversity of the 'reference healthy population' used for generating percentile data, and how does the software account for factors beyond age and gender?; Can the software differentiate between subtle pathological changes associated with early-stage neurodegenerative diseases and normal anatomical variations, given the reported Dice coefficients for segmentation accuracy?; What are the computational time requirements for processing a typical T1 MRI series from input to report generation, and how does this performance scale for high-throughput clinical environments?; Are there validation studies on the software's performance in longitudinal analysis, specifically its ability to reliably track volumetric changes in brain structures over time for individual patients and manage serial scan registration?